Microbix viral antigens are used by 90% of diagnostic manufacturers world wide
MISSISSAUGA, Ontario, Oct. 30, 2013 - Microbix Biosystems Inc. (MBX:TSX), a Canadian biotechnology company, is coming off a record sales year for its diagnostic antigens as it heads to MEDICA, the world’s largest annual medical trade fair, in Düsseldorf, Germany, Nov. 20-23, with new and improved products that make for better detection of children’s diseases, in particular.
“Demand from manufacturers of diagnostic tests for Microbix viral antigens has risen dramatically in the past four years,” says Kevin Koole, Microbix Director of Sales and Marketing. “But the past 12 months have been particularly exciting for us. Compared to the previous period, we have experienced strong double-digit growth in the volume of antigen we’ve shipped.”
At the Microbix booth, Koole will introduce MEDICA visitors to the company’s new Respiratory Syncytial Virus (RSV) detection product and its improved Rotavirus Antigen. RSV is the most common cause of lung and airway infections in young children. Rotavirus is the most common cause of childhood infectious diarrhea.
“At MEDICA we’ll also be talking about the excellent progress we’ve been making on our purified native Dengue 1-4 serotypes that complement our already successful Dengue 2 antigen,” adds Koole. Microbix serotypes will enable more accurate detection of different pathogenic organisms connected with the deadly Dengue hemorrhagic virus spread in the tropics by mosquitoes.
Other Microbix antigens include:
Hepatitis A virus
Herpes Simplex 1&2
Respiratory Syncytial virus
At MEDICA 2013, Microbix will be exhibiting in Hall 3 at booth K53 as part of the Ontario, Canada pavilion under the red maple leaf and welcomes the media, visitors, and old friends.
For further information, please contact Kevin Koole at 1-905-361- 8910 x228 by telephone or email@example.com by email.
As well, please visit our microbix.com website and also search for us in “Companies & Products” on the medica-tradefair.com portal.